Argen X Quote - ARGX

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

402.70

Bid

400.50

Ask

409.90

Volume

32,740

401.50 Day's Range 409.00

271.00 52 Week Range 494.10

Market Cap

23.938B

Previous Close

404.40

Open

405.90

Last Trade

402.7

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

60,528

Shares Outstanding

59,194,000

Dividend Yield

PE Ratio

-80.79

Earnings Per Share (EPS)

-4.98

Revenue

1.27B

Net Profit

-295.05M

Sector

Coml Physical, Biologcl Resh

Industry

Coml Physical, Biologcl Resh

Website

www.argenx.com

Headquarters

Amsterdam, North Holland, Nld

Founded

1970

Argen X SE is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker ARGX. The last closing price for Argen X was 404.40 €. Over the last year, Argen X shares have traded in a share price range of 271.00 € to 494.10 €.

Argen X currently has 59,194,000 shares outstanding. The market capitalization of Argen X is 23.94 € billion. Argen X has a price to earnings ratio (PE ratio) of -80.79.

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of...

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in...

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development...

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in...

argenx announces results of Annual General Meeting of Shareholders

May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe...

argenx to Present at BofA Securities 2024 Health Care Conference

May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over...

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-14.3	-3.42925659472	417	419.3	398.2	56277	406.93458475	DE
4	47.8	13.4685826994	354.9	432.9	342.8	75033	389.2659909	DE
12	49.1	13.8857466063	353.6	432.9	323.4	60528	364.14687513	DE
26	51	14.5009951663	351.7	432.9	322.5	60721	360.10914245	DE
52	56.7	16.387283237	346	494.1	271	63473	396.5099485	DE
156	135.8	50.8804795804	266.9	494.1	224.1	65122	344.68052045	DE
260	275.4	216.339355852	127.3	494.1	93.05	79237	260.27904955	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SFDNXT Energy Solutions Inc	$ 0.275 (19.57%)	3.5k
GECGlobal Education Communities Corp	$ 0.355 (14.52%)	500
DSVDiscovery Silver Corp	$ 1.07 (12.63%)	617.37k
BSXBelo Sun Mining Corp	$ 0.045 (12.50%)	4k
YRBYorbeau Resources Inc	$ 0.045 (12.50%)	284k
CRWNCrown Capital Partners Inc	$ 2.21 (-26.58%)	1.37k
VGCXVictoria Gold Corp	$ 0.81 (-14.74%)	3.02M
DYADynaCERT Inc	$ 0.225 (-13.46%)	505.07k
GFRGreenfire Resources Ltd	$ 9.80 (-12.58%)	17.5k
SGNLSignal Gold Inc	$ 0.095 (-9.52%)	529.1k
TDToronto Dominion Bank	$ 75.29 (-0.76%)	15.05M
TRPTC Energy Corporation	$ 51.60 (-1.13%)	9.62M
BNSBank of Nova Scotia	$ 61.65 (-0.66%)	9.43M
SDESpartan Delta Corp	$ 4.10 (-3.53%)	6.41M
ENBEnbridge Inc	$ 48.53 (-0.86%)	6.11M